Roche's ADC drug Hersele's new indication is approved again to protect the long-term survival of patients with HER2-positive advanced breast cancer

Nowadays, when cancer treatment methods are becoming more abundant, innovative drugs bring new hope to patients, and at the same time, they often create a large burden due to the price
.
To this end, all sectors of society have successively launched various patient care projects including urban customized medical insurance
.
With the approval of Hersele’s late indications, it will also be included, such as Huhuibao
.
This will greatly reduce the economic burden of patients, and bring more hope of cure for the majority of breast cancer patients in China
.

About EMILIA research

The EMILIA study is an international multi-center, randomized, open-label Phase III clinical trial that compared Hercelium® (enmetrastuzumab) with capecitabine/lapatinib for previous use of trastoma Efficacy and safety of patients with HER2-positive locally advanced breast cancer or metastatic breast cancer treated with luzumab combined with paclitaxel.
A total of 991 patients were randomly assigned to Hercelium® (Enmetrastuzumab) at a 1:1 ratio.
Anti-) group (3.
6 mg/kg, intravenously administered once every 3 weeks) or control group (oral capecitabine 1,000 mg/m2, bid, d1-14, repeated every 3 weeks; combined oral lapatinib 1,250 mg , Qd, d1-21 continuous oral administration)
.

Reference materials:

1.
2020 Standardized Diagnosis and Treatment Guidelines for Advanced Breast Cancer in China

2.
Dawood S, Broglio K, Buzdar AU, et al.
Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review.
J Clin Oncol.
2010 Jan 1; 28(1):92-8.

3.
Swain SM et al.
, Lancet Oncol.
2020;21(4):519-530